Patient perceived changes in sexual dysfunction after initiation of natalizumab for multiple sclerosis

Area of Science:

• Neurology
• Sexual Medicine
• Quality of Life Research

Background:

• Sexual dysfunction is a prevalent, yet often overlooked, secondary symptom in multiple sclerosis (MS).
• Sexual dysfunction significantly diminishes health-related quality of life (HRQoL) for individuals with MS.
• Natalizumab, a disease-modifying therapy for relapsing MS, has demonstrated improvements in HRQoL aspects like fatigue and cognition.

Purpose of the Study:

• To investigate the impact of natalizumab on sexual dysfunction in patients with relapsing MS.
• To explore the potential correlation between improvements in fatigue and sexual dysfunction following natalizumab treatment.

Main Methods:

• A 24-week, single-center, open-label, single-arm study evaluated perceived changes in sexual dysfunction.
• Adult patients with relapsing MS initiating natalizumab and reporting baseline sexual dysfunction were enrolled.
• The primary endpoint was the change in the MS Intimacy and Sexuality Questionnaire-19 (MSISQ-19) score from baseline to week 24.

Main Results:

• Patients treated with natalizumab showed a statistically significant improvement in sexual dysfunction after 24 weeks (MSISQ-19 subscale change: -0.6976, p=0.02).
• The study demonstrated a positive effect of natalizumab on sexual dysfunction within the initial 24 weeks of therapy.

Conclusions:

• Sexual dysfunction is a critical issue impacting HRQoL in MS patients and warrants further research.
• These findings suggest natalizumab may positively influence sexual dysfunction, offering potential benefits beyond its established efficacy in MS.
• Further investigation into the relationship between disease-modifying therapies and sexual dysfunction in MS is crucial for patient care and treatment decisions.